{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86","upperLimit":"99","value":"96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"12 Month Overall survival is defined as the proportion of patients to still be alive after 12 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.","id":"OG000","title":"All Treated Patients"}],"paramType":"NUMBER","populationDescription":"All of the 64 participants that were eligible and began treatment were evaluated.","reportingStatus":"POSTED","timeFrame":"From baseline to death","title":"Overall Survival (12 Month)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}